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While the benefit of oral anticoagulants (OACs) for stroke prevention in patients with atrial fibrillation (AF) is well established, it is not known
whether oral anticoagulation is indicated in patients with atrial high-rate episodes (AHRE) recorded on a cardiac implantable electronic device,
sometimes also called subclinical AF, and lasting for at least 6 min in the absence of clinically diagnosed AF. Clinical evidence has shown that
short episodes of rapid atrial tachycarrhythmias are often detected in patients presenting with stroke and transient ischaemic attack. Patients
with AHRE have a higher likelihood of suffering from subsequent strokes, but their stroke rate seems lower than in patients with diagnosed AF,
and not all AHRE episodes correspond to AF. The prognostic and pathological significance of AHRE is not yet fully understood. Clinical trials of
OAC therapy are being conducted to determine whether therapeutic intervention would be beneficial to patients experiencing AHRE in terms
of reducing the risk of stroke.
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Introduction
Atrial fibrillation (AF) leads to abnormalities of intracardiac blood
flow, endocardium and blood constituents, conferring a prothrom-
botic state.1 The disorder is associated with a five-fold increased risk
of ischaemic stroke and is encountered in 40% patients with is-
chaemic stroke or transient ischaemic attack (TIA).2 Approximately
15 million people worldwide suffer from a stroke each year3 and of
these, at least 15% have been related to clinically diagnosed AF.2
Strokes associated with AF have a poor prognosis compared with
strokes of other aetiologies.4 One-quarter of ischaemic strokes
are of unknown cause, usually designated cryptogenic, and undiag-
nosed AF may be a potential aetiologic factor.2 While AF typically
presents with palpitations, dyspnoea, chest pain, and fatigue, it
may also be asymptomatic.5,6 Furthermore, atrial tachycardias
(ATs) are heterogeneous in terms of the type of atrial arrhythmias,
their duration, resulting ventricular rate and degree of irregularity,
and underlying cardiovascular conditions.
Paroxysmal atrial fibrillation (PAF), as opposed to permanent AF,
is transient and infrequent, and, like permanent AF, may be asymp-
tomatic. Data suggest that asymptomatic PAF episodes occur with
much greater frequency than symptomatic PAF.7 Recent studies
have focused on establishing the frequency of short asymptomatic
episodes of AF, which have been termed atrial high-rate episodes
(AHREs). AHREs are detected in patients with pacemaker or im-
plantable cardioverter defibrillator (ICD) devices and often occur
in the absence of AF diagnosed by the usual methods (i.e. electro-
cardiogram, Holter monitor).8 The definition of AHREs refers to
episodes with a duration of .6 min, mainly to reduce the inclusion
of electrical artefacts, and is usually confined to patients who do not
have clinically detected AF.9 Such patients are at elevated risk of
stroke and may have unmet anticoagulation needs. However, it
must be stressed that not all studies have used this definition of
AHRE. A definition of 5 min’ duration has been used in some key
studies, based on previously published data that suggested that a
5 min cutoff excludes most episodes of oversensing.10 While the
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benefits of oral anticoagulation for stroke prevention in patients
with clinical AF are well established, it is not known whether the
same risk-benefit ratio exists for OAC therapy in patients with
AHREs. This article aims to discuss the incidence of AHREs, review
the evidence of their association with stroke risk and discuss the
need for anticoagulation in these patients.
Current strategies for stroke
prevention in atrial fibrillation
In the past, the prescription and persistence with anticoagulation
therapy has been suboptimal, largely due to the disadvantages asso-
ciated with vitamin K antagonists (VKAs) and fear of bleeding among
both patients and physicians, although clinical evidence has estab-
lished that the risk of ischaemic stroke without anticoagulant treat-
ment is higher than the risk of intracranial bleeding.11 In the era
before non-vitamin K antagonist oral anticoagulants (NOACs) be-
came available, ,50% of at-risk AF patients were effectively anti-
coagulated, and up to 70% of patients with known AF who had
already suffered an ischaemic stroke were not receiving anticoagu-
lant therapy to prevent AF-related stroke at the time of the
stroke.12 – 14 Current AF guidelines recommend the consideration
of NOACs in AF patients with a CHA2DS2VASc ≥1.15 However,
NOACs are generally underutilized:16 the PREFER in AF registry,
a prospective, observational multi-centre registry conducted in se-
ven EU countries, found considerable variation in anticoagulation
management strategies. Non-vitamin K antagonist oral anticoagu-
lants were used in 6% of patients.17,18 Clinical trial data on the
four currently approved NOACs (dabigatran, apixaban, rivaroxa-
ban, and edoxaban) show that NOACs are non-inferior or superior
to warfarin with regard to the efficacy outcome of stroke and sys-
temic embolism (SE) and in addition are consistently associated
with a reduction of life threatening or critical organ bleeding, such
as intracranial bleeds.19 – 23 A meta-analysis of all trials suggests
that NOACs are equal to or superior to warfarin in terms of risk
reduction of stroke or systemic embolic events, while NOAC ther-
apy is associated with a lower risk of severe, especially intracranial
haemorrhage.19
All available data supporting the use of oral anticoagulation for
stroke prevention in AF have been obtained from patients with clin-
ically diagnosed (ECG documented) AF. The effectiveness and
safety of NOACs in patients with AHRE/subclinical AF (SCAF)
but without ECG documented AF is unknown. If it were demon-
strated that NOACs provide a clinical benefit in such patients, po-
tential stroke prevention could be improved, given that these
patients represent a high percentage of patients with cardiac rhythm
management devices. To optimize NOAC therapy, a greater under-
standing of stroke risk patients with PAF including SCAF/AHRE is
needed. However, it is worth noting that it is very likely that not
all strokes seen in patients with either AF or AHRE are of
cardio-embolic origin. Atrial fibrillation could be a coincidental find-
ing in many patients, given their burden of underlying cardiovascular
disease, which could independently cause ischaemic stroke and AF.
Incidence of atrial high-rate events
Advances in pacemaker and ICD technology, which allow long-term
continuous heart rhythm monitoring, have enabled the continuous
assessment of atrial tachyarrhythmias in patients with an atrial
lead.24,25 The significance and occurrence of AHRE is increasingly
recognized, but these events are often not acted upon in patients
presenting with stroke and TIA. An analysis of the AFFIRM study
(Atrial Fibrillation Follow-up Investigation of Rhythm Management)
found that 12% of patients were asymptomatic at baseline. These
patients had a lower incidence of serious heart disease but more
cerebrovascular events (CVEs).26 Among patients presenting with
an acute stroke, 5% have previously undetected AF on admission.
Subsequent intermittent 12-lead ECG or ambulatory Holter ECG
monitoring has identified higher incidences of undiagnosed AF in
stroke survivors: 10% in unselected stroke survivors and 30% in
those who presented with cryptogenic stroke (Figure 1).27–31
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OAC: 10.1% in the ICM group versus 4.6% in the control at 6 months (P = 0.04) and
14.7% versus 6.0% at 12 months (P = 0.007). By 12 months, 97.0% of patients in
whom artial fibrillation had been detected were receiving OAC.
Follow-up ICM
AF Rate
Control
AF rate
6 months 8.9% 1.4%
12 months 12.4% 2.0%
36 months 30.0% 3.0%
HR 95% CIs P-value 
6.63 1.90–21.74 0.0006
7.32 2.57–20.81 <0.0001
8.78 3.47–22.19 <0.0001 6 m 12 m 36 m
Figure 1 Detection of AF among patients with cryptogenic stroke or transient ischaemic attack randomized to an ICM or control (conventional
follow-up). Adapted from Sanna et al.29
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Atrial high-rate episodes can be detected on a surface ECG, but
documentation is less likely since monitoring is either not continu-
ous or relatively short in duration. One study of patients (n ¼ 142)
with cryptogenic stroke but with no history of AF, found that long-
term heart rhythm monitoring detected silent AF in 46% of
patients.32 Another study reviewed the records of 1128 consecutive
patients attending a stroke clinic and identified 426 patients with
definite stroke and TIA. These patients underwent Holter monitor-
ing for a mean of 22.6 h. Episodes of PAF lasting.30 s in 11 patients
(2.5%) and nonsustained atrial arrhythmias in another 28 patients
(6.5%).33 A study of a consecutive series of 56 patients with crypto-
genic TIA/stroke used 21-day monitoring with mobile cardiac out-
put telemetry. Results showed that 5.3% of cryptogenic stroke
patients had episodes of PAF lasting .30 s, and 23% had episodes
lasting ,30 s.34
Most of the data on AHRE has been obtained from patients with
pacemakers or ICDs. Many of these patients have sinus node disease
and/or ventricular pacing which are associated with a higher inci-
dence of AF; therefore, the prevalence of AHRE may be lower in
the general population.35,36
Atrial high-rate episode and stroke
risk
A growing body of clinical data support the hypothesis that AHRE
are associated with an elevated risk of stroke (Table 1). Atrial diag-
nostics ancillary study of the MOde Selection Trial (MOST) found
that patients (n ¼ 312) with sinus node dysfunction who experi-
enced AHRE (.220 beats per minute [bpm] lasting at least
5 min) were more likely to have adverse clinical outcomes, including
a higher incidence of stroke, death, and subsequent AF than patients
without AHRE (Figure 2). Over 6 years, the incidence of AHREs was
associated with an increased total mortality (hazard ratio [HR] 2.48;
95% confidence interval [CI] 1.25–4.91, P ¼ 0.0092), death/non-
fatal stroke (HR 2.79; 95% CI 1.51–5.15, P ¼ 0.0011), and the devel-
opment of clinical AF (HR 5.93; 95% CI 2.88–12.2, P ¼ 0.0001).
However, there was insufficient evidence to stimulate significant dis-
cussion about whether an atrial arrhythmia of 5 min in duration war-
rants anticoagulation treatment.37
The Relationship between daily atrial tachyarrhythmia burdEN
from Implantable device Diagnostics and Stroke risk (TRENDS)
was a prospective, observational study enrolling patients (n ¼
2486) with ≥1 stroke risk factor (heart failure, hypertension, age
≥65 years, diabetes, or prior thromboembolic event [TE]) receiving
pacemakers or defibrillators that monitor AT. During a mean
follow-up of 1.4 years, the rate of TEs was low compared with
that in patients with AF diagnosed by traditional modalities and simi-
lar CHADS2 scores, but the risk of TEs was doubled in patients with
an atrial tachyarrhythmia/AF burden .5.5 h compared with those
with no atrial tachyarrhythmia/AF. The annualized TE risk (including
TIA) was 1.1% for zero, 1.1% for low, and 2.4% for high AT burden.
Compared with zero burden, adjusted HRs (95% CIs) in the low and
high burden subsets were 0.98 (0.34–2.82, P ¼ 0.97) and 2.20
(0.96–5.05, respectively, P ¼ 0.06).38
The ASSERT trial (ASymptomatic atrial fibrillation and Stroke
Evaluation in pacemaker patients and the atrial fibrillation Reduction
atrial pacing Trial) monitored patients (n ¼ 2580, hypertensive,
aged ≥ 65 years, with a recently implanted ICD and no history of
AF) for 3 months to detect AHRE (episode of atrial rate .190 bpm
for.6 min, termed SCAF in this study) and followed them for a mean
of 2.5 years.9 Subclinical AF was detected in 261 (10.1%) patients with-
in 3 months of device implantation (see Table 2).9 Subclinical AF was
associated with an increased risk of clinical AF (HR 5.56; 95% CI 3.78–
8.17; P, 0.001) and of ischaemic stroke or SE (HR 2.49; 95% CI 1.28–
4.85; P ¼ 0.007). Of 51 patients who had an ischaemic stroke or SE,
SCAF was detected in 11 (21.6%) by 3 months, and none had clinical
AF by 3 months. The population attributable risk of stroke or SE
associated with SCAF was 13%. The presence of SCAF was predictive
of stroke or SE even after adjustment for predictors of stroke (HR
2.50; 95% CI 1.28–4.89; P ¼ 0.008).9
Surprisingly, no correlation was found in ASSERT between AHRE
episodes and a history of stroke. This highlights the possible limita-
tions of restricting the sampling period to the first 3 months of the
study, and it has been suggested that AHRE may be a transient phe-
nomenon related to lead implantation.39 This phenomenon was
noted in the Silent Atrial Fibrillation detection with stored EGMs
registry study, which examined the incidence, duration, and predic-
tors of AHRE in patients without previous clinically diagnosed AF
after dual-chamber pacemaker implantation. At 6-month follow-up,
10% of patients experienced one or more AHRE (defined as an atrial
tachyarrhythmia with a rate ≥180 beats/min lasting ≥5 min) usually
lasting 5–60 min. Some patients had AHRE only within the first 30
days after implantation, suggesting that these AHRE may have been
related to lead insertion.40
The Carelink/VA study was a case crossover study that examined
the records of patients (n ¼ 9850) with ICDs. The study defined
‘significant’ AF as ≥5.5 h of AF on ≥1 day in the preceding 30
days (TRENDS criteria), and compared its presence during the per-
iod 30 days prior to the stroke with the control period (91–120
days prior to the stroke). Among 187 eligible strokes, significant
AF was associated with a four-fold increased risk of stroke (HR ¼
4.33. 95% CI 1.19–23.7). The stroke risk was highest in the 5–10
days after AF episode and rapidly declined after 10 days.41
Other studies have also added to the body of evidence for the as-
sociation between AHREs and stroke. The EURObservational Re-
search Programme Pilot survey on Atrial Fibrillation found that
asymptomatic AF is associated with high thromboembolic risk.42
In the Belgrade Atrial Fibrillation Study, a single-centre registry study
(n ¼ 1010), 10-year estimates of survival free of progression of AF
(log-rank test ¼ 33.4, P, 0.001) and ischaemic stroke (log-rank
test ¼ 6.2, P ¼ 0.013) were significantly worse for patients with
asymptomatic AF at diagnosis compared with those with symptom-
atic AF. In the multivariable Cox regression analysis, intermittent
asymptomatic AF was significantly associated with progression to
permanent AF (HR 1.6; 95% CI 1.1–2.2; P ¼ 0.009).43 An analysis
of .10 000 patients from the SOS AF project (Stroke preventiOn
Strategies based on Atrial Fibrillation, information from implanted
devices), which included patients without permanent AF, found
that 43% of patients experienced at least 1 day with at least 5 min
of AF burden and that AF burden was an independent predictor
of ischaemic stroke. A threshold of 1 h of AF burden was associated
with the highest risk of ischaemic stroke (HR 2.11; 95% CI 1.22–
3.64, P ¼ 0.008).44
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These data have established a clear association between AHRE
and increased risk of stroke, but a high proportion of ischaemic brain
lesions could be subclinical and therefore the embolic risk underes-
timated. A recent study (n ¼ 75) found an association between
AHRE and ischaemic brain lesions detected by CT scan. Multivari-
able analyses showed that the presence of AHRE .5 min was an in-
dependent predictor for silent ischaemic brain lesions (HR 9.64
[1.86–50.02; P, 0.05]).45
The health risk conferred by AHRE may extend beyond increased
risk of stroke: a study of patients (n ¼ 224) with no history of AF who
underwent dual-chamber pacemaker implantation found that AHRE
were associated with a significant increase in cardiovascular mortality
(HR 2.80; 95% CI 1.24–6.31; P ¼ 0.013) and stroke mortality (HR
9.65; 95% CI 1.56–59.9; P ¼ 0.015), with a trend towards increased
all-cause mortality (HR 1.79; 95% CI 0.98–3.26; P ¼ 0.059).46
Implications of study findings on
atrial high-rate episodes and stroke
risk
Mechanisms of thrombogenesis
Atrial fibrillation may trigger chronic changes in the atria and has
been linked with changes in atrial structure and endothelial
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Table 1 Summary of studies investigating the association between AHREs and stroke risk
Trial Study type and
duration
Study population Criteria for the diagnosis of
AHRE
Outcomes
MOST29 Subgroup analysis of
RCT, 6 years
n ¼ 312, median age 74 years,
55% female, and 60% had a
history of SND
Atrial rate .220 bpm for 10
consecutive beats
Compared with control, AHREs
were associated with increased
total mortality (HR 2.48 95% CI
1.25–4.91, P ¼ 0.0092), death or
non-fatal stroke (HR 2.79; 95% CI
1.51–5.15, P ¼ 0.0011), and AF
(HR 5.93; 95% CI 2.88–12.2,
P ¼ 0.0001)
TRENDS30 Prospective
observational
study, mean
follow-up 1.4 years
n ¼ 2486 with ≥ 1 risk factor
for stroke
AT/AF burden ¼ longest total AT/AF
duration on any given day during
the prior 30-day period and
classified as subsets: zero, low
(,5.5 h [median duration]), and
high (≥ 5.5 h)
Compared with zero burden, AF
burden was associated with
increased TE: HR 0.98; 95% CI
0.34–2.82, P ¼ 0.97) and 2.20;
95% CI 0.96–5.05, P ¼ 0.06), for
low and high, respectively
ASSERT31 Prospective
observational
study, mean
follow-up 2.5 years
n ¼ 2580, age ≥ 65 years, with
hypertension and no history
of AF
Atrial rate .190 bpm for .6 min By 3 months, AHREs occurred in
10.1%. AHREs were associated
with an increased risk of clinical
AF (HR 5.56; 95% CI 3.78–8.17;
P, 0.001) and of ischaemic
stroke or SE (HR 2.49; 95% CI
1.28–4.85; P ¼ 0.007). After
adjustment for predictors of
stroke AHREs remained
associated with stroke/SE (HR
2.50; 95% CI 1.28–4.89;
P ¼ 0.008)
Carelink/VA34 Case crossover study,
analysis of data 30
days preceding a
stroke
n ¼ 9850, median age 68 years,
99% male, and 98% had a
defibrillator
≥5.5 h of AF on ≥1 day in the
preceding 30 days
AHREs was associated with a
four-fold increased risk of stroke
within 30 days (OR ¼ 4.33. 95%
CI 1.19–23.7) Risk was highest in
the 5–10 days after AHRE and
rapidly declined after 10 days
Belgrade
Atrial
Fibrillation
Study35
Single-centre registry
study and mean
follow-up
9.9+6.1 years
n ¼ 1100, mean age
52.7+12.2 years, 13.3%)
had asymptomatic AF
Asymptomatic presentation of first
diagnosed AF
Ischaemic stroke risk (log-rank
test ¼ 6.2, P ¼ 0.013) was
significantly worse for patients
with asymptomatic AF compared
with those with symptomatic AF
SOS AF
project36
Pooled analysis of
individual patient
data from five
prospective studies
n ¼ 10 016, median age 70
years. Pts without
permanent AF with ICDs
were included if they had at
least 3 months of follow-up
Device-detected AF. Cutoff points of
AF burden defined as: 5 min, 1, 6,
12, and 23 h
AF burden 1 h was associated with
the risk of ischaemic stroke (HR
2.11, 95% CI 1.22–3.64,
P ¼ 0.008)
AF, atrial fibrillation; AHRE, atrial high-rate event; AT, atrial tachycardia; bpm, beats per minute; RCT, randomized controlled trial; SE, systemic embolism; SND, sinus node; TE,
thromboembolic event.
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function,47,48 inflammation,49,50 and prothrombotic activity.51,52 Ab-
normal changes shown in the vessel and atrial wall, in flow and in
blood constituents contribute to thrombogenesis.52,53 However,
despite evidence of a temporal association and possible mechanistic
link between AHRE and stroke risk, the role of AHRE in these pro-
cesses has not been established. It is possible than rather than caus-
ing embolic events, AHRE are simply a marker for cardio-embolic
risk.54 Thromboembolic risk likely involves a complex interplay of
atrial arrhythmia, atrial myopathy, endothelial dysfunction related
to comorbidity and abnormal haemostasis.55 In AF, the majority
of left atrial (LA) thrombi involve the LA appendage. In a recent
study (n ¼ 201), a quarter of patients with PAF demonstrated a
prothrombotic AF left atrial appendage (LAA) pulse wave Doppler
phenotype, i.e. a discordance between the existence of sinus
rhythm on ECG and the impaired mechanical LAA function re-
vealed by Doppler that promotes blood clotting, despite concur-
rent ECGs showing sinus rhythm. This study demonstrates that
prolonged ECG monitoring may not detect the patients at risk
and may provide a mechanistic explanation of the thrombotic risk
in PAF patients.56 The occurrence of AHRE may trigger chronic
0.18
AHREs by 1 year
No AHREs by 1 year
P = 0.001
0.16
0.14
0.12
0.1
Ev
en
t r
at
e
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0.04
0.02
0
12 18 24
Months after substudy enrolment
30 36
Figure 2 The MOST study: Kaplan–Meier plot of death or non-fatal stroke after 1 year of the atrial diagnostics ancillary study in patients with
atrial high-rate episodes vs. those without atrial high-rate episodes. Source: Glotzer et al.37
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Table 2 Results of the ASSERT clinical trial
Event Device-detected atrial tachyarrhythmia Device-detected atrial
tachyarrhythmia present vs. absent
Absent n5 2319 Present n5 261
Events %/year Events %/year RC 95% CI P
All patients
Ischaemic stroke or SE 40 0.69 11 1.69 2.49 1.28–4.85 0.007
Vascular death 153 2.62 19 2.92 1.11 0.69–1.79 0.67
Stroke/MI/vascular death 206 3.53 29 4.45 1.25 0.85–1.84 0.27
Clinical AF or flutter 71 1.22 41 6.29 5.56 3.76–8.17 ,0.001
Event Device-detected atrial tachyarrhythmia Device-detected atrial
tachyarrhythmia present vs. absent
Absent n5 1786 Present n5 191
Events %/year Events %/year RC 95% CI P
Patients with CHADS score ≥2
Ischaemic stroke or SE 40 0.70 10 2.14 2.67 1.32–5.38 0.006
Vascular death 153 2.67 16 3.42 1.08 0.64–1.82 0.77
Stroke/MI/vascular death 206 3.59 25 5.35 1.25 0.82–1.90 0.30
Clinical AF or flutter 58 1.31 30 6.42 5.29 3.40–8.24 ,0.001
Source: Healey et al.9
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changes in the atria that result in thrombus formation after the oc-
currence of SCAF.
In an attempt to better understand the relationship between
AHRE and stroke pathogenesis, a sub-analysis of the ASSERT trial
focused on the 51 patients that experienced stroke or SE after 3
months. Of these, 26 (51%) had SCAF and 18 patients (35%) had
SCAF before stroke/SE. Only four patients (8%) had SCAF detected
within 30 days before stroke/SE, among whom one patient experi-
enced SCAF at the time of the stroke. Eight patients (16%) had SCAF
detected only after their stroke, despite continuous monitoring for a
median duration of 228 days (25th to 75th percentile, 202–719) be-
fore their event.54 Most SCAF occurring before embolic events was
considerably ,48 h in duration, which is conventionally (but with
little or no scientific justification) believed to be the minimum dur-
ation required for thrombus to form in the LAA before cardiover-
sion.57,58 In addition, a subgroup analysis of TRENDS found that the
majority of CVEs/SE in this population did not occur within 30 days
of AT/AF episodes, suggesting either that the thrombus formation
or embolization may be delayed or that the mechanisms of CVE/
SE in patients with implantable devices may involve mechanisms
other than cardio-embolism due to AT (Figures 3 and 4).59 These
findings have led to a reassessment of the mechanisms by which
AF causes embolic events. If a causal relationship exists, it is likely
to be more complex than first believed.1,52
An analysis of two multi-centre studies, involving 560 heart failure
patients using home-monitoring technology, found that patients
with device-detected detected AHRE lasting .3.8 h over 24 h
were nine times more likely to develop TEs (P ¼ 0.006).60 In add-
ition, data from the Registry of Atrial Tachycardia And Atrial Fibril-
lation Episodes In The Cardiac Rhythm Management Device
Population RATE registry showed that among patients with ICDs,
those who experienced long episodes of AHREs were at greater
risk of all adverse events than patients with no episodes (OR
1.56). Long episodes of AT/AF were also associated with a greater
risk of AF hospitalization (OR 5.86). Short episodes of AT/AF were
not associated with increased risk.61 It is noteworthy that in both
studies, there were wide variations in timing between the AHRE
and the occurrence of TEs.
Implications for clinical practice
Study findings have indicated that patients experiencing AHRE are at
elevated risk for stroke, TIA, and SE and raise the question: should
these patients receive oral anticoagulation therapy for stroke pre-
vention? Currently, the majority of patients with AHRE do not re-
ceive OACs, suggesting that physicians require clarification of the
risks associated with AHRE before routinely prescribing treat-
ment.62,63 These clinically silent atrial tachyarrhythmias may not
have the same prognosis as AF and the impact of OAC therapy
may be significantly different in this population. The ASSERT trial
suggested that the stroke risk associated with AHREs is lower
than that associated with AF, although study populations differed
significantly.9,64 While the data from MOST, TRENDS, and ASSERT
support a link between pacemaker-AHRE and the occurrence of
stroke or SE, these studies are limited by their small sample size
and limited number of clinical events. A systematic literature review
and meta-analysis investigated the detection rate of different ECG-
monitoring techniques to detect AF in patients who had a TIA or an
ischaemic stroke. A total of 32 observational or randomized studies
were identified, with 5038 participants. The detection rate for AF
was 11.5%, but a wide variation was reported in methods, observa-
tion time, and minimal duration of arrhythmia to be defined as AF.
The review was also limited by small sample sizes.65
In a retrospective analysis of patients from a single academic hos-
pital (n ¼ 445), pacemaker-detected AF was present in 55.3% pa-
tients. Anticoagulants were used in 35.3% of patients with
pacemaker-detected AF. Among these patients, OACs were used
more frequently in those who also had clinical AF (58.9%) compared
with those without (23.7%, P, 0.001).62 Patients with AHRE/SCAF
are usually excluded from clinical trials of OACs. In the RE-LY trial,
patients with PAF were included if they had at least two
TRENDS: 2,486 patients
device +1 stroke risk factor 
40 (1.6%)
had CVE/SE 
No AT/AF
prior to CVE/SE
in 20 (50%)
29 (73%) zero
AT/AF burden
within 30 days
prior to CVE/SE 
Last episode
168 +199 days
(3–642 days)
before CVE/SE 
14 (70 %) not
in AT/AF at
time of CVE/SE 
AT/AF during
CVE/SE in 6
(30%) 
9 (45%) no
AT/AF in
30 days prior
to CVE/SE 
5 (35%)
AT/AF in
30 days prior
to CVE/SE 
AT/AF prior to
CVE/SE in 20
(50%)
Figure 3 The TRENDS study: baseline characteristics of study participants. Adapted from Daoud et al.59
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documented episodes of AF, but data from pacemakers or ICDs
could only be used to record one of these episodes.66 In other ma-
jor NOAC trials, patients with SCAF were not excluded; inclusion
criteria were two or more episodes of AF or flutter, as documented
by electrocardiography in ARISTOTLE,21 AF documented on elec-
trocardiography in ROCKET AF22 and AF documented by means of
an electrical tracing within the preceding 12 months in ENGAGE
AF-TIMI 48.23 However, no clinical trial to date has investigated
the use of OACs in patients with AHREs and no clinical AF, and
this represents a substantial unmet need.
There is a need for high-quality evidence to inform updated guide-
lines. Expert opinions suggest that anticoagulation therapy should be
individualized and promoted in SCAF according to the CHADS2
score.67–69 At the third joint consensus conference of the German At-
rial Fibrillation Network (AFNET) and the European Heart Rhythm
Association on AF, an algorithm for management of patients with
AHREs was proposed and a modified version is shown in Figure 5.71
The results of the Carelink/VA and other studies support a strat-
egy of transient use of rapidly acting OACs linked to the onset of
AHREs.41 However, prescription of OAC therapy on this basis in
patients with pacemakers/ICDs requires continuous monitoring of
device data. Remote home monitoring of pacemaker/ICD data
with automatic daily surveillance has proved effective and safe.72 IM-
PACT (The IMPACT of Biotronik Home Monitoring Guided Antic-
oagulation on Stroke Risk in Patients with ICD and CRT-D Devices)
was an interventional therapy trial (n ¼ 2718) designed to test the
hypothesis that initiation and withdrawal of OAC therapy based on
occurrence of AHRE detected by continuous ambulatory monitor-
ing of pacemaker/ICD data may reduce the combined rate of stroke,
SE, and major bleeding compared with conventional clinical manage-
ment. In the intervention group, OAC was administered based on
patient-specific risk stratification following detection of AHRE.
The OAC was withdrawn if AHREs did not recur within a prede-
fined period. Recently published data show that 945 patients
(34.8%) developed AT, 264 meeting study anticoagulation criteria.
Primary events (2.4 vs. 2.3 per 100 patient-years) did not differ be-
tween groups (HR 1.06; 95% CI 0.75–1.51; P ¼ 0.732). Although
AT burden was associated with thromboembolism, there was
no temporal relationship between AT and stroke. The study con-
cluded that the strategy of early initiation and interruption of antic-
oagulation based on remotely detected AT did not prevent
thromboembolism and bleeding. However, in this trial the antith-
rombotic agent used was mainly a VKA. It is not known whether
the results would have been different if NOACs, which have
more rapid onset and offset of action and are safer regarding intra-
cranial bleedings, had been used.73
Recently, small, leadless subcutaneous insertable cardiac moni-
tors (ICM) with remote data transmission capabilities (Reveal
XTTM and Reveal LINQTM, Medtronic Inc.) have been developed.
These allow remote and continuous evaluation of a patient for AF
recurrences. The Rhythm Evaluation for AntiCoagulaTion with
COntinuous Monitoring (REACT.COM) pilot study evaluated the
feasibility of transient ‘pill-in-the-pocket’ anticoagulation based on
the results of daily remote transmissions from an ICM. Inclusion cri-
teria were a CHADS2 score of 1 or 2, non-permanent AF, no docu-
mented AF lasting over a 1 h on two consecutive months on a
previously implanted ICM, and compliance with an NOAC for 30
consecutive days prior to enrolment. Participants were maintained
on aspirin therapy and transmitted data daily from their ICM, allow-
ing detection of AF within 24 h of an episode. If an AF episode
lasting ≥ 1 h was detected, NOACs were prescribed for 30 days.74
While the ability to detect AHRE in patients with pacemakers/
ICDs involves little additional cost, the same is not true of a wider
patient population. Long-term monitoring for AF raises questions
about cost-effectiveness. A small (n ¼ 24) study of patients aged un-
der 75 years who had undergone cryptogenic stroke found an unex-
pectedly low incidence of AF and AHRE.75 However, the
CRYSTAL-AF (CRYptogenic STroke and underlying. AtriaL
AHRE on implanted device
History of ischemic stroke or AF
YES NO
Look for presence of AF
12-lead, rhythm strip, Holter ECG
Reassess periodically 
*These criteria are arbitrary but
reasonable given current evidence
 No clinical AFAF documentedStandard
anticoagulation
Use AHRE
to inform
management
Consider anticoagulation
if AHRE >24 hours and
CHA2DS2-VASc ≥2 for men,
and ≥3 for women* 
Figure 5 Suggested treatment algorithm for management of patients with AHREs. Adapted from Kirchhof et al.70
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Fibrillation) study was a large (n ¼ 441) randomized, controlled
study involving long-term monitoring with an ICM. At 12 months
follow-up, AF had been detected in six times more patients with
ICM compared with conventional follow-up (Figure 3).29 In the EM-
BRACE (Atrial Fibrillation After a Cerebral Ischaemic Event) trial
(n ¼ 572) non-invasive ambulatory ECG monitoring for 30 days sig-
nificantly improved the detection of AF by a factor of more than five
and nearly doubled the rate of anticoagulant treatment, compared
with the short-duration ECG monitoring.30 On the other hand, a re-
cent observational study of younger patients (n ¼ 56, mean age
48+ 9 years) showed a low rate of PAF after cryptogenic stroke
or stroke of known cause.
Experts have suggested that screening procedures take into ac-
count risk factors for AF including diabetes mellitus,34 and other re-
cently established factors including obesity and obstructive sleep
apnoea.76,77 A recent cost-effectiveness analysis found that mass
screening of 75/76-year-old individuals for asymptomatic AF, using
intermittent ECG recording and a decision analysis simulation mod-
el, resulted in 263 fewer patient-years with undetected AF, and
therefore 8 fewer strokes, 11 more life-years, and 12 more
quality-adjusted life-years per 1000 screened individuals. The
screening protocol was therefore considered cost effective.78
To optimize therapy for AHRE, physicians need to identify high-
risk patients.79,80 Numerous potential biomarkers have been inves-
tigated, including haemostatic markers of coagulation and fibrinolyt-
ic activity,81 plasma von Willebrand levels,82 and cardiac biomarkers
such as troponin and natriuretic peptides.83,84 However, to date,
none have been found to be sufficiently useful and practical to war-
rant adoption in influencing clinical decision-making.85 In patients
with a history AF, the combination of AF duration and CHADS2
score was predictive of ischaemic TEs.86,87
The ARTESiA (Apixaban for the Reduction of Thrombo-
Embolism in Patients With Device-Detected Sub-Clinical Atrial Fib-
rillation) trial is currently recruiting.88 The study aims to enrol 4000
high-risk (CHA2DS2VASc score ≥ 3) participants with permanent
pacemakers or ICDs, and at least one episode of SCAF ≥6 min in
duration (atrial rate.175/min if an atrial lead is present), but no sin-
gle episode .24 h in duration. Subclinical AF requires electrogram
confirmation (at least one episode) unless ≥6 h in duration. Patients
will be randomized to receive apixaban or aspirin. The primary effi-
cacy outcome measures are a composite of ischaemic stroke and SE;
the primary safety outcome measure is the incidence of major
bleeds.
The AFNET association and the European Society of Cardiology
are initiating a new trial, NOAH (non-vitamin K antagonist oral an-
ticoagulants in patients with atrial high-rate episodes). Patients aged
65 years or older with documented AHRE and one additional
CHA2DS2VASc factor will be randomized to edoxaban or aspirin/
placebo, depending on the indications for antiplatelet therapy.89
Summary and concluding remarks
Following advances in cardiac monitoring, it is likely that AHRE will
be increasingly reported in the future. A growing body of clinical trial
and registry study data has established a link between AHRE and the
risk of stroke and SEs, and it is evident that stroke risk should be
managed in all patients with AHREs. However, several questions
remain unanswered. Future studies require a standardized definition
of AHRE, as past studies have used various definitions. Future stud-
ies should also consider how AHREs are diagnosed; a recent study
found significant variation in diagnostic accuracy among devices and
according to level of operator expertise.90 The pathological and
prognostic significance of AHRE has not been fully established.
There is a need to identify and validate further markers of risk in pa-
tients with AHRE. Finally, the use of oral anticoagulation for stroke
prevention in patients with AHRE must be evaluated. Given the risks
and inconvenience of OAC therapy, there are currently insufficient
data to support their routine use in patients with AHRE, but no clin-
ically detected AF.
Future studies should include information on demographics,
stroke characteristics (subtypes and severity), measures of AF bur-
den, subclinical ischaemic events, and long-term incidence of recur-
rent CE events in patients with AHRE. Ongoing studies should
address the key question of whether AHRE are a direct cause of
stroke or a marker of a population at risk that would benefit from
sustained anticoagulation. Cost-effectiveness should be assessed.
Future studies should also address the impact of treatment on pa-
tient symptoms and quality of life. Such studies will not only help
to standardize current clinical approaches, which are variable and
poorly informed, but also help elucidate the relationship between
ATs and stroke as well as helping inform shared decision-making,
clinical guideline development, and health policy.
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